Učitavanje...
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
BACKGROUND: In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in terms of the overall survival, but offered better progression-free survival. However, the effects of lenvatinib in uHCC patie...
Spremljeno u:
| Izdano u: | World J Clin Cases |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Baishideng Publishing Group Inc
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7322437/ https://ncbi.nlm.nih.gov/pubmed/32607334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i12.2574 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|